Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 1993Journal of Clinical Oncology

Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

MKM. KaufmannWJW. JonatUAUlrich Abel

Discussion

Loading...

Member takes

Overview

Randomized trials compare chemotherapy and endocrine therapy outcomes in women with node-positive breast cancer, suggesting distinct age-related effects.

Key Points

  • To compare the effectiveness of different adjuvant therapies in women with node-positive breast cancer based on age and recurrence risk.
  • Two randomized trials conducted with 747 patients ≤ 65 years old with node-positive breast cancer.
  • Patients stratified based on hormone receptor status and treated with either chemotherapy or endocrine therapy across two risk groups (low and high risk).
  • Comparative analysis of disease-free survival and overall survival in specified age groups after treatment.
  • In low-risk patients, CMF and Tam showed equivalent effectiveness, but CMF resulted in higher DFS (P=0.01) and OS (P=0.002) in women ≤ 49 years.
  • In women > 50 years old, Tam was superior to CMF in DFS (P=0.003) and OS (P=0.5).
  • In high-risk patients, the combination of AC and Tam was equivalent to AC alone, but AC plus Tam improved DFS (P=0.01) for women > 50 years.

Cite This Study

Kaufmann et al. (1993) studied this question.

synapsesocial.com/papers/6a72c2f2e5469ee92be29000https://doi.org/10.1200/jco.1993.11.3.454
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.1997 · 94 citations
  2. 2Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.1991 · 163 citations
  3. 3Adjuvant Sequential Chemotherapy With Doxorubicin Plus Cyclophosphamide, Methotrexate, and Fluorouracil (ACMF) With Concurrent Radiotherapy in Resectable Advanced Breast Cancer2000 · 6 citations
  4. 4Multimodal therapy for locally advanced breast cancer1986 · 44 citations
  5. 5CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer2001 · 8 citations